Darolutamide plus ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer
Study · company release · The Manila Times · 2026-10-24. Number 5 in the UrologyWatch Top 5 for October 26, 2026.
A phase 3 trial found that adding darolutamide to ADT and radiation therapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone in men with prostate cancer at high risk of recurrence.
Why it matters: A phase 3 trial found darolutamide plus ADT and radiation cut metastasis or death risk, which can be considered in high-risk recurrent prostate cancer pending full details.
Limitation: Specific endpoint definitions, follow-up duration, and absolute event rates are not detailed in this brief report.
Source: The Manila Times
Loading today's edition…